TABLE 1.

Comparison of immunity after immunization with different preparations^a

Immunogen	Phaseb	Frequency (%)				CTL (LU)
		Tetramer	ICG	ICG/Tet%c	Peptide	HSV	HSV/Pep%c
rhsp70-SSIEFARL	Acute	7.8	6.9	88	(1)	72	64	89	(4)
Memory	2.1	1.1	52			15	4			27
UV-inactivated HSV	Acute	6.0	5.8	97	(2)	53	50	94	(5)
	Memory	3.2	2.9	91		36	32	89
VvgB	Acute	8.1	7.3	90	(3)	82	72	87	(6)
	Memory	2.6	1.8	69		32	22	68

^aThe mice were sacrificed on day 7 (acute) and day 90 (memory) after the second immunization and analyzed for tetramer-positive CD8 T-cells, peptide-induced IFN-γ production, and CTL activity by ⁵¹Cr release assay as described in Materials and Methods. The tetramer and ICG values are the percentage of double-positive cells (CD8⁺/Tet⁺ and CD8⁺/IFN-γ⁺, respectively). The CTL data are expressed as lytic units (LU) and show results accrued from only the UV-treated HSV, VvgB-, and rhsp70-peptide-immunized groups for SSIEFARL-pulsed and HSV-infected targets. The experiments were done with 10 individual mice in each group at a given time point. The data represent the average result. Individual values were used to compute the statistics by using SPSS software to analyze the significance by the dependent sample t test.

^bAcute phase, 7 days after the second immunization; memory phase, 90 days after the second immunization.

^cICG/Tet%, (intracellular IFN-γ-positive cells/tetramer-positive cells) × 100; HSV/Pep%, (HSV targets/peptide targets) × 100. P values are indicated by numbers in parentheses as follows: 1, P < 0.0001 (t₉ = 13.93); 2, P < 0.001 (t₉ = 4.87); 3, P < 0.0001 (t₉ = 10.74); 4, P < 0.001 (t₉ = 17.92); 5, P < 0.242 (t₉ = 1.37); and 6, P < 0.008 (t₉ = 4.99).